Expanded Access Policy 

We believe the best way to understand the potential of SKY-0515 is to study its safety and efficacy in controlled clinical trials. While we recognize there may be potential interest in accessing SKY-0515 outside of the formal clinical trial setting, we do not offer expanded access to SKY-0515 at this time. Currently, our efforts are focused on advancing SKY-0515 to make it available to appropriate patients as soon as possible through robust clinical trials and subsequent regulatory approvals.

 

If you are a health care provider who is interested in learning more about SKY-0515, or a physician, patient or caregiver with questions about participation in our clinical trials, please submit a request to Sky0515trials@skyhawktx.com. Skyhawk Therapeutics will acknowledge inquiries as soon as possible, usually within 5 business days of receipt. We remain dedicated to advancing SKY-0515 efficiently and will continue to evaluate expanded access opportunities as our efforts advance. Please check this page periodically as we reserve the right to update this policy at any time.